# GRAMD4

## Overview
GRAMD4, or GRAM domain containing 4, is a gene that encodes a protein involved in the regulation of apoptosis, a form of programmed cell death. The protein encoded by GRAMD4 is characterized by the presence of a GRAM domain, which is implicated in membrane-associated processes. Functionally, GRAMD4 plays a significant role in mitochondrial outer membrane permeabilization, facilitating the release of apoptogenic factors such as cytochrome c and Smac/Diablo, thereby promoting apoptosis. It interacts with key apoptotic regulators, including BCL2 and BAX, through a putative BH3 motif, influencing the apoptotic pathway independently of transcriptional regulation (G.2012An). Clinically, GRAMD4 has been associated with cranial size abnormalities in Phelan-McDermid Syndrome, highlighting its potential role in developmental processes (Nevado2022Variability; Sarasua2023Head). Additionally, its expression is modulated in response to DNA-PK inhibition, linking it to cellular responses to DNA damage (Yang2018Inhibition).

## Clinical Significance
GRAMD4 has been implicated in various clinical conditions, particularly in relation to cranial size abnormalities in Phelan-McDermid Syndrome (PMS). Studies have identified GRAMD4 as one of the candidate genes associated with macrocephaly in individuals with PMS. This association is particularly noted in cases where there are larger deletions on chromosome 22q13, which include GRAMD4, suggesting its potential role in cranial size alterations (Sarasua2023Head). GRAMD4 is located in a genomic interval linked to macrocephaly, and its interaction with PIAS1, a member of the ubiquitin protein family, has been experimentally demonstrated. This interaction is relevant because PIAS1 is related to macro/microcephaly in certain syndromes, indicating that GRAMD4 may influence cranial size through this pathway (Nevado2022Variability).

The gene is also considered to have a high probability of loss-of-function intolerance, with a pLI score greater than 0.9, suggesting that having only one functioning copy could be pathogenic. This haploinsufficiency is likely to contribute to the phenotypic variability observed in PMS, particularly in head size variations (Sarasua2023Head).

## Interactions
GRAMD4 is involved in several protein interactions that play a crucial role in apoptosis. It is identified as a p73 primary-response gene that efficiently induces mitochondrial outer membrane permeabilization, leading to the release of cytochrome c and Smac/Diablo into the cytoplasm. GRAMD4 interacts with BCL2, promoting the relocalization and oligomerization of BAX at the mitochondria. This interaction is independent of transactivation effects at the BCL2 or BAX promoters, suggesting that GRAMD4 operates through post-translational mechanisms. A putative BH3 motif within GRAMD4, spanning amino acids 218-230, is thought to be involved in its interaction with BCL2. Deletion of a region encompassing amino acids 92-176 in GRAMD4 disrupts its interaction with BCL2, likely due to a conformational change affecting the BH3 domain (G.2012An).

In the context of DNA-PK inhibition, GRAMD4 expression is increased, which correlates with the induction of the p73 apoptosis pathway. This modulation of GRAMD4 expression is associated with a decrease in the Bcl-2/Bax protein ratio, enhancing apoptosis in A549 cells subjected to X-ray irradiation (Yang2018Inhibition).


## References


[1. (Nevado2022Variability) Julián Nevado, Sixto García-Miñaúr, María Palomares-Bralo, Elena Vallespín, Encarna Guillén-Navarro, Jordi Rosell, Cristina Bel-Fenellós, María Ángeles Mori, Montserrat Milá, Miguel del Campo, Pilar Barrúz, Fernando Santos-Simarro, Gabriela Obregón, Carmen Orellana, Harry Pachajoa, Jair Antonio Tenorio, Enrique Galán, Juan C. Cigudosa, Angélica Moresco, César Saleme, Silvia Castillo, Elisabeth Gabau, Luis Pérez-Jurado, Ana Barcia, Maria Soledad Martín, Elena Mansilla, Isabel Vallcorba, Pedro García-Murillo, Franco Cammarata-Scalisi, Natálya Gonçalves Pereira, Raquel Blanco-Lago, Mercedes Serrano, Juan Dario Ortigoza-Escobar, Blanca Gener, Verónica Adriana Seidel, Pilar Tirado, and Pablo Lapunzina. Variability in phelan-mcdermid syndrome in a cohort of 210 individuals. Frontiers in Genetics, April 2022. URL: http://dx.doi.org/10.3389/fgene.2022.652454, doi:10.3389/fgene.2022.652454. This article has 28 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2022.652454)

[2. (Yang2018Inhibition) Lina Yang, Xinrui Yang, Yiwei Tang, Defu Zhang, Lijie Zhu, Shengnan Wang, Bo Wang, and Tao Ma. Inhibition of dna‑pk activity sensitizes a549 cells to x‑ray irradiation by inducing the atm‑dependent dna damage response. Molecular Medicine Reports, March 2018. URL: http://dx.doi.org/10.3892/mmr.2018.8828, doi:10.3892/mmr.2018.8828. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/mmr.2018.8828)

[3. (Sarasua2023Head) Sara M. Sarasua, Jane M. DeLuca, Curtis Rogers, Katy Phelan, Lior Rennert, Kara E. Powder, Katherine Weisensee, and Luigi Boccuto. Head size in phelan–mcdermid syndrome: a literature review and pooled analysis of 198 patients identifies candidate genes on 22q13. Genes, 14(3):540, February 2023. URL: http://dx.doi.org/10.3390/genes14030540, doi:10.3390/genes14030540. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/genes14030540)

[4. (G.2012An) Robert G. Hawley, Yuzhong Chen, Irene Riz, and Chen Zeng. An integrated bioinformatics and computational biology approach identifies new bh3-only protein candidates. The Open Biology Journal, 5(1):6–16, May 2012. URL: http://dx.doi.org/10.2174/1874196701205010006, doi:10.2174/1874196701205010006. This article has 8 citations.](https://doi.org/10.2174/1874196701205010006)